A Comparison between Abacavir and Efavirenz as the Third Drug Used in Combination with a Background Therapy Regimen of 2 Nucleoside Reverse‐Transcriptase Inhibitors in Patients with Initially Suppressed Viral Loads-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Comparison between Abacavir and Efavirenz as the Third Drug Used in Combination with a Background Therapy Regimen of 2 Nucleoside Reverse‐Transcriptase Inhibitors in Patients with Initially Suppressed Viral Loads

Published:2006-07 Issue:1 Volume:194 Page:20-28
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:J INFECT DIS

Author:

Cozzi‐Lepri Alessandro,Luca Andrea De,Phillips Andrew N.,Bongiovanni Marco,Giambenedetto Simona Di,Mena Maurizio,Moioli Maria Cristina,Arlotti Massimo,Sighinolfi Laura,Narciso Pasquale,Lichtner Miriam,Cauda Roberto,Monforte Antonella d’Arminio, , ,

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/194/1/20/18011237/194-1-20.pdf

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV;Cochrane Database of Systematic Reviews;2013-06-05

2. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study;AIDS;2007-10

3. Nucleoside and Nucleotide Reverse Transcriptase Inhibitors in Children;Clinical Drug Investigation;2007

4. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir;AIDS;2006-10-24

5. Tuberculosis and HIV Co-Infection;Drugs;2006

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP